gptkbp:instance_of
|
gptkb:sneaker
|
gptkbp:bfsLayer
|
4
|
gptkbp:bfsParent
|
gptkb:Allergan
|
gptkbp:activities
|
increases tear production
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
gptkbp:average_temperature
|
room temperature
|
gptkbp:class
|
gptkb:drug
anti-inflammatory
|
gptkbp:clinical_trial
|
Phase III
long-term treatment
DEWS study
RESTORE study
SYSTANE study
|
gptkbp:contraindication
|
hypersensitivity to cyclosporine
|
gptkbp:current_use
|
gptkb:Sjogren's_syndrome
allergic conjunctivitis
eyelid inflammation
|
gptkbp:dosage_form
|
emulsion
|
gptkbp:education
|
report any severe eye pain
avoid touching the dropper tip
wait 15 minutes before using other eye drops
|
gptkbp:form
|
gptkb:sneaker
|
gptkbp:formulation
|
0.05% solution
|
gptkbp:frequency
|
twice daily
|
https://www.w3.org/2000/01/rdf-schema#label
|
Restasis
|
gptkbp:ingredients
|
gptkb:cyclosporine_A
|
gptkbp:invention
|
gptkb:2022
|
gptkbp:is_used_for
|
treating dry eye disease
|
gptkbp:manager
|
topical
|
gptkbp:manufacturer
|
gptkb:Allergan
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
gptkbp:packaging
|
single-use vials
|
gptkbp:pharmacokinetics
|
local action
minimal systemic absorption
|
gptkbp:population
|
adults
children over 16 years
|
gptkbp:previous_name
|
gptkb:battle
|
gptkbp:price
|
approximately $500 per month
|
gptkbp:provides_information_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:European_Society_of_Ophthalmology
|
gptkbp:requires
|
prescription only
|
gptkbp:side_effect
|
headache
itching
eye pain
foreign body sensation
redness of the eye
burning sensation in the eyes
discharge from the eye
dryness of the eye
|
gptkbp:traded_on
|
gptkb:Restasis
|